Towards Healthcare
Ambulatory Electrocardiography (ECG) Market Size and Demand

Ambulatory Electrocardiography (ECG) Market Business Expansion

The ambulatory electrocardiography (ECG) market is projected to grow US$ 743.02 mn in 2025 to witness US$ 1122.40 mn by 2030. The ambulatory ECG market is growing due to rising cardiovascular disease rates, driving demand for portable heart monitoring. Technological advancements, including AI integration, enhance device accuracy. North America leads with advanced healthcare infrastructure, while Asia Pacific sees rapid growth fueled by rising CVD cases and government support.

The global ambulatory electrocardiography (ECG) market was estimated at US$ 630 million in 2023 and is projected to grow to US$ 1561.24 million by 2034, rising at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2034. The demand for ambulatory ECGs is growing due to the advantages they provide over traditional ECGs. Portable ECGs are useful when it comes to ECG monitoring for prolonged surveillance. 

Ambulatory Electrocardiogra Hy (ECG) Market Revenue 2023 - 2034

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

The ambulatory electrocardiography (ECG) market deals with the manufacturing and distribution of ECG monitoring devices. These devices are portable and are designed for prolonged and continuous surveillance of cardiac rhythm. Portable ECG devices are useful in monitoring cardiac rhythm in the natural environment of the patients. Ambulatory devices are highly useful in detecting infrequent or transient cardiac events that can be used by professionals to analyze any serious health risks in the future.

The demand for ambulatory ECG is growing due to the growing number of people with cardiovascular diseases (CVDs). To date, it is the leading cause of death worldwide, according to the WHO. Healthcare professionals recommend the use of portable ECGs for people who are at a high risk of cardiovascular diseases, such as obese people, people with a family history of cardiovascular diseases, diabetic people, or people who have already gone through healthcare procedures for cardiovascular issues.

For instance,

  • It is estimated that, between 2025 and 2050, there will be a 90.0% increase in the prevalence of CVDS, a 73.4% increase in crude mortality, and a 54.7% increase in crude DALYs. The deaths associated with CVDs are estimated to increase from 20.5 million in 2025 to 35.6 million in 2050.

In August 2024, Sunfox Technologies, a business located in Dehradun, secured an extra Rs 15 crore in a pre-series fundraising round. The money raises a total of Rs 20 crore, building on a prior investment of Rs 5 crore from USAID through SAMRIDH Health and LetsVenture. Sunfox plans to use this additional funding to expand quickly in India and internationally, concentrating on growing its flagship product, Spandan, a portable ECG gadget that runs on a smartphone.

In May 2023, the closure of HeartBeam, Inc.'s secondary offering of 16,666,666 shares of its common stock was announced. With this funding, HeartBeam will be able to finance its next clinical and regulatory milestones for its HeartBeam AIMIGoTM system and prepare for 2024 commercialization. HeartBeam received $23.2 million in net proceeds from the transaction after subtracting offering costs, placement agent charges, and discounts.

Technological Advancements Means Advanced ECG Devices

Technological advancements are significantly improving the accuracy and efficiency of various medical devices, including ECG. AI is becoming a part of ECG in diagnosis, stratification and management. AI is useful in interpreting data & prediction, noticing ECG abnormalities, and other factors that can be useful in mitigating serious health issues in the future. With advancements in developing better AI and machine learning algorithms, the ambulatory electrocardiography (ECG) market has the opportunity to use these advanced algorithms to make even more powerful ECG devices in the future.

For instance,

  • In June 2024, AliveCor declared the KardiaTM 12L ECG System and KAITM 12L AI technology to be commercially available after receiving FDA approval. This is the first AI in the world that can identify potentially fatal cardiac problems, such as heart attacks, using a smaller lead set. The Kardia 12L ECG System is the first portable 12-lead ECG system with AI capabilities and a distinctive single-cable architecture. It has a revolutionary proprietary technology.

Noises Generated by Ambulatory ECG is a Drawback

Since there is more noise and artifacts created during everyday activities than during hospital monitoring, beat identification is more difficult for ambulatory monitoring. An ECG signal-to-noise ratio (SNR) that is low can occur when a patient engages in a variety of high-intensity physical activities.

Regional Insights

Growing CVDs is Driving North America’s Market

North America dominated the ambulatory electrocardiography (ECG) market in 2023. North America is technologically advanced, with advanced healthcare infrastructure and organizations that continuously make efforts to provide innovative solutions to existing problems. The region holds a dominating position in technology, healthcare, and research & development. The U.S. and Canada are the two major countries that promote the growth of the market in North America.

The largest share of North America’s ambulatory electrocardiography (ECG) market was captured by the U.S. in 2023. The dominance of the country is due to advanced healthcare infrastructure, the presence of key market players, investments in R&D, and government support. The presence of organizations like the U.S. FDA gives an advantage to the U.S. because these organizations provide funding, guidance, and approvals for new devices, technology, therapy, therapeutics, drugs, and others.

Apart from this, the country is among the top countries with CVDs. It is because of the sedentary lifestyle, unhealthy eating habits, and physical inactivity. From 2020 to 2050, the cases of CVDs are expected to increase to 55.13% in the U.S. The growing cases of CVDs and telehealth in the U.S. are significantly pushing organizations to develop ambulatory ECG and healthcare users to use these devices for health monitoring and preventive care.

Cases of CVD in the U.S., 2020 v/s 2050 (In Millions)

Partnerships and Government Support is Promoting Asia Pacific

Asia Pacific is expected to grow at the fastest rate during the forecast period. The ambulatory electrocardiography (ECG) market in Asia Pacific is growing due to the growing number of CVD cases. The major contributors to the market’s growth are China, India, Japan, and South Korea.0

For instance,

  • According to the National Institutes of Health, around 330 million people in China are affected by CVD, and a large population is at risk of getting CVD due to smoking, obesity, dyslipidemia, physical inactivity, etc. 
  • In India, CVD is the leading cause of death, and the country is going to have a healthcare burden of US$ 2.17 trillion from 2012-2030.

To reduce the growing burden on the healthcare system of CVDs, the governments in the Asia Pacific are taking significant steps such as financial investments, awareness programs, health policies, and providing incentives. Apart from this, market key players are also establishing their branches and launching new devices in countries such as India and China, which have a high potential for growth.

For instance,

  • In May 2024, the Japanese medical equipment company's Indian division, OMRON Healthcare India, established a partnership with AliveCor India, a major provider of personal electrocardiogram (ECG) technology. In addition to being the leading provider of blood pressure monitors in India, OMRON Healthcare India revealed that this agreement enables the firm to provide AI-based portable ECG technology.

Segmental Insights

By type, the portable segment held the largest share of the ambulatory electrocardiography (ECG) market in 2023. There are several advantages of using portable ECG monitors, such as early detection of heart conditions, continuous monitoring, patient empowerment, and cost-effectiveness. These devices are highly useful in telehealth or remote patient monitoring.

The patch segment is estimated to grow at the fastest rate during the forecast period. These devices can be used for extended periods, require less material for making, and are small, lightweight, and adhesive. These devices provide clinical flexibility, continuity, and convenience.

For instance,

  • In October 2023, for ambulatory ECG monitoring, Dozee teamed up with Wellysis, a spin-off from Samsung's SDS Digital Health group, to provide its FDA-approved S-Patch Ex ECG monitoring gadget. A wireless ECG patch for ongoing heart rhythm monitoring and an analytical platform make up the solution.

By application, the hospital segment held the dominant share of the ambulatory electrocardiography (ECG) market in 2023. The majority of patients visit the hospital for regular health check-ups, to take health advice, and hospital admissions for prolonged care, due to which these devices are dominantly used by hospital staff. Hospitals are preferred due to the presence of all the necessary resources, including equipment, medicines, and healthcare professionals.

The home segment is anticipated to grow at the fastest rate in the ambulatory electrocardiography (ECG) market during the forecast period. The segment is growing due to the growing demand for remote health monitoring. It is highly useful in the case of patients who cannot commute to the hospital due to old age, disability, or long distances.

Recent Developments

  • In August 2024, the Zio monitor and Zio long-term continuous (LTCM) ambulatory ECG monitoring service was commercially launched in Austria, the Netherlands, Spain, and Switzerland, according to iRhythm Technologies, Inc.
  • In May 2024, Vivalink's all-inclusive technological solution for Holter monitoring and Mobile Cardiac Telemetry (MCT) will be introduced by the leading supplier of digital healthcare solutions.

Top Companies in the Ambulatory Electrocardiography (ECG) Market

  • GE Healthcare
  • Hill-Rom
  • Mindray Medical
  • Philips Healthcare
  • Compumed
  • Mortara Instrument
  • Schiller
  • Cardionet
  • Spacelabs Healthcare
  • Nihon Kohden

Segments Covered in the Report

By Type

  • Portable
  • Patch
  • Other

By Application

  • Hospital
  • Holter Service Provider
  • Home
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Insight Code: 5266
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.

FAQ's

Event monitors (Subtypes: looping and non-looping), Holter monitors, patch recorders, real-time monitors, and implantable loop recorders.

Numerous methods can be used to conduct ambulatory ECG monitoring for as little as 24 to 48 hours or as long as months or years.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, American Heart Association, World Heart Federation.